QUEBEC CITY, QUEBEC--(Marketwire - June 25, 2008) - Medicago Inc. (TSX VENTURE: MDG) today announced additional positive results for the Company’s H5N1 Avian Influenza VLP vaccine from a preclinical immunogenicity study performed in ferrets, the most predictive animal model for evaluating the effectiveness of influenza vaccines in humans. The Company’s H5N1 VLP vaccine induced high levels of antibodies that neutralized strains of H5N1 circulating virus beyond the strain used to develop the original vaccine. Cross-reactivity was demonstrated against three of the deadliest strains of H5N1: the Turkey strain (clade 2.2), the Anhui strain (clade 2.3) and the Vietnam strain (clade 1).
